KIT 突变转录本水平对监测 t(8;21)型急性髓性白血病可测量残留疾病的有用性。

IF 3.3 4区 医学 Q2 HEMATOLOGY
Yuan Sun, Xu Wang, Wen-Min Chen, Yue Hao, Ling-Di Li, Jin-Ying Li, Kai Sun, Zong-Yan Shi, Hao Jiang, Qian Jiang, Xiao-Jun Huang, Ya-Zhen Qin
{"title":"KIT 突变转录本水平对监测 t(8;21)型急性髓性白血病可测量残留疾病的有用性。","authors":"Yuan Sun,&nbsp;Xu Wang,&nbsp;Wen-Min Chen,&nbsp;Yue Hao,&nbsp;Ling-Di Li,&nbsp;Jin-Ying Li,&nbsp;Kai Sun,&nbsp;Zong-Yan Shi,&nbsp;Hao Jiang,&nbsp;Qian Jiang,&nbsp;Xiao-Jun Huang,&nbsp;Ya-Zhen Qin","doi":"10.1002/hon.3264","DOIUrl":null,"url":null,"abstract":"<p>In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KIT<sup>mut</sup>) DNA level is reportedly predictive of relapse in <i>t</i> (8; 21) acute myeloid leukemia (AML). However, the usefulness of KIT<sup>mut</sup> transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 <i>t</i> (8; 21) AML patients with KIT<sup>mut</sup> (D816V/H/Y or N822K) were tested for KIT<sup>mut</sup> transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KIT<sup>mut</sup> were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KIT<sup>mut</sup>-high (KIT_H) group and the KIT<sup>mut</sup>-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (<i>p</i> = 0.0040 and 0.021, respectively) and Course 2 consolidation (<i>p</i> = 0.018 and 0.011, respectively) but not at diagnosis and CR. The &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with &gt;3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KIT<sup>mut</sup> and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in <i>t</i> (8; 21) AML patient with KIT mutation.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia\",\"authors\":\"Yuan Sun,&nbsp;Xu Wang,&nbsp;Wen-Min Chen,&nbsp;Yue Hao,&nbsp;Ling-Di Li,&nbsp;Jin-Ying Li,&nbsp;Kai Sun,&nbsp;Zong-Yan Shi,&nbsp;Hao Jiang,&nbsp;Qian Jiang,&nbsp;Xiao-Jun Huang,&nbsp;Ya-Zhen Qin\",\"doi\":\"10.1002/hon.3264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KIT<sup>mut</sup>) DNA level is reportedly predictive of relapse in <i>t</i> (8; 21) acute myeloid leukemia (AML). However, the usefulness of KIT<sup>mut</sup> transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 <i>t</i> (8; 21) AML patients with KIT<sup>mut</sup> (D816V/H/Y or N822K) were tested for KIT<sup>mut</sup> transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KIT<sup>mut</sup> were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KIT<sup>mut</sup>-high (KIT_H) group and the KIT<sup>mut</sup>-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (<i>p</i> = 0.0040 and 0.021, respectively) and Course 2 consolidation (<i>p</i> = 0.018 and 0.011, respectively) but not at diagnosis and CR. The &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with &gt;3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KIT<sup>mut</sup> and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in <i>t</i> (8; 21) AML patient with KIT mutation.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"42 2\",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.3264\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3264","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

据报道,除了 RUNX1::RUNX1T1 转录本水平外,使用 KIT 突变体(KITmut)DNA 水平监测可测残留疾病也可预测 t (8; 21) 急性髓性白血病(AML)的复发。然而,KITmut 转录本水平的作用仍不清楚。我们使用数字聚合酶链反应检测了 52 名 t (8; 21) 型急性髓性白血病患者在诊断时和治疗期间采集的 202 份骨髓样本的 KITmut(D816V/H/Y 或 N822K)转录本水平。通过对以下各时间点的复发情况进行接收者操作特征曲线分析,确定了 KITmut 的各个最佳临界值:诊断时、获得完全缓解 (CR) 后、疗程 1 和疗程 2 巩固后。利用截断值将患者分为 KITmut -高(KIT_H)组和 KITmut -低(KIT_L)组。KIT_H 组患者在第一疗程巩固治疗后(p = 0.0040 和 0.021,分别为 0.0040 和 0.021)和第二疗程巩固治疗后(p = 0.018 和 0.011,分别为 0.0040 和 0.021),无复发生存率(RFS)和总生存率(OS)明显低于 KIT_L 组患者,但在诊断和 CR 时则不明显。RUNX1::RUNX1T1转录物水平降低3个对数值(11/45;24.4%)的患者的RFS与Mut和RUNX1::RUNX1T1转录物水平降低3个对数值(11/45;24.4%)的患者的RFS相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia

In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KITmut) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of KITmut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 t (8; 21) AML patients with KITmut (D816V/H/Y or N822K) were tested for KITmut transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KITmut were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KITmut-high (KIT_H) group and the KITmut-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (p = 0.0040 and 0.021, respectively) and Course 2 consolidation (p = 0.018 and 0.011, respectively) but not at diagnosis and CR. The <3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with >3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with <3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KITmut and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in t (8; 21) AML patient with KIT mutation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hematological Oncology
Hematological Oncology 医学-血液学
CiteScore
4.20
自引率
6.10%
发文量
147
审稿时长
>12 weeks
期刊介绍: Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信